Vanda Pharmaceuticals Inc.
VNDA
$6.42
$0.152.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -9.61% | 1.70% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -9.61% | 1.70% | |||
| Cost of Revenue | -17.58% | 29.76% | |||
| Gross Profit | -9.04% | 0.15% | |||
| SG&A Expenses | 8.55% | 4.49% | |||
| Depreciation & Amortization | 13.41% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.48% | 11.45% | |||
| Operating Income | -24.46% | -28.99% | |||
| Income Before Tax | -27.42% | -33.86% | |||
| Income Tax Expenses | -99.86% | 1,877.83% | |||
| Earnings from Continuing Operations | 65.60% | -525.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 65.60% | -525.11% | |||
| EBIT | -24.46% | -28.99% | |||
| EBITDA | -25.24% | -31.02% | |||
| EPS Basic | 65.81% | -525.07% | |||
| Normalized Basic EPS | -20.16% | -41.06% | |||
| EPS Diluted | 65.68% | -525.07% | |||
| Normalized Diluted EPS | -20.16% | -41.06% | |||
| Average Basic Shares Outstanding | 0.61% | 0.01% | |||
| Average Diluted Shares Outstanding | 0.61% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||